Palivizumab is a humanized monoclonal antibody that binds to respiratory syncytial virus (RSV) glycoprotein fusion protein (F), and inhibits viral entry into cells, thereby reducing RSV associated hospitalizations.
The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants.
iBioLaunch-produced palivizumab has been shown to bind inactivated RSV, indicating that it recognizes F antigen presented on the virus’ surface.
In addition, plant-produced palivizumab was found to show 50% plaque reduction compared to palivizumab manufactured in recombinant mammalian cells.